 | • レポートコード：MRC2Q12-18904 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、カルシニューリン阻害剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 カルシニューリン阻害剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 カルシニューリン阻害剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 カルシニューリン阻害剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのカルシニューリン阻害剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のカルシニューリン阻害剤の売上および2028年までの予測に焦点を当てています。 カルシニューリン阻害剤のグローバル主要企業には、Accord Healthcare、Dr. Reddy Labs、Panacea Biotec Ltd.、Sandoz、Mylan、Abbott、Roche Pharma、Astellas、Takeda、Tecoland、ScinoPharm、RPG Life Science、Cayman Chemical、BioVision、Santa Cruz Biotechnology、Merck、AbMole、Selleck Chemicals、BOC Sciences、Biosynth Carbosynth、AG Scientific、TOKU-E、LKT Laboratories、Allergan、Mimetogen Pharmaceuticals、Otsuka Pharmaceutical、Regenerx Biopharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 カルシニューリン阻害剤市場は、タイプとアプリケーションによって区分されます。世界のカルシニューリン阻害剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 タクロリムス、ピメクロリムス、シクロスポリンA 【アプリケーション別セグメント】 慢性移植片対宿主病、アトピー性皮膚炎、脂漏性皮膚炎、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - カルシニューリン阻害剤製品概要 - タイプ別市場（タクロリムス、ピメクロリムス、シクロスポリンA） - アプリケーション別市場（慢性移植片対宿主病、アトピー性皮膚炎、脂漏性皮膚炎、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のカルシニューリン阻害剤販売量予測2017-2028 - 世界のカルシニューリン阻害剤売上予測2017-2028 - カルシニューリン阻害剤の地域別販売量 - カルシニューリン阻害剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別カルシニューリン阻害剤販売量 - 主要メーカー別カルシニューリン阻害剤売上 - 主要メーカー別カルシニューリン阻害剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（タクロリムス、ピメクロリムス、シクロスポリンA） - カルシニューリン阻害剤のタイプ別販売量 - カルシニューリン阻害剤のタイプ別売上 - カルシニューリン阻害剤のタイプ別価格 ・アプリケーション別市場規模（慢性移植片対宿主病、アトピー性皮膚炎、脂漏性皮膚炎、その他） - カルシニューリン阻害剤のアプリケーション別販売量 - カルシニューリン阻害剤のアプリケーション別売上 - カルシニューリン阻害剤のアプリケーション別価格 ・北米市場 - 北米のカルシニューリン阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のカルシニューリン阻害剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのカルシニューリン阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のカルシニューリン阻害剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のカルシニューリン阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のカルシニューリン阻害剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のカルシニューリン阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のカルシニューリン阻害剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのカルシニューリン阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のカルシニューリン阻害剤市場規模（トルコ、サウジアラビア） ・企業情報 Accord Healthcare、Dr. Reddy Labs、Panacea Biotec Ltd.、Sandoz、Mylan、Abbott、Roche Pharma、Astellas、Takeda、Tecoland、ScinoPharm、RPG Life Science、Cayman Chemical、BioVision、Santa Cruz Biotechnology、Merck、AbMole、Selleck Chemicals、BOC Sciences、Biosynth Carbosynth、AG Scientific、TOKU-E、LKT Laboratories、Allergan、Mimetogen Pharmaceuticals、Otsuka Pharmaceutical、Regenerx Biopharmaceuticals ・産業チェーン及び販売チャネル分析 - カルシニューリン阻害剤の産業チェーン分析 - カルシニューリン阻害剤の原材料 - カルシニューリン阻害剤の生産プロセス - カルシニューリン阻害剤の販売及びマーケティング - カルシニューリン阻害剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - カルシニューリン阻害剤の産業動向 - カルシニューリン阻害剤のマーケットドライバー - カルシニューリン阻害剤の課題 - カルシニューリン阻害剤の阻害要因 ・主な調査結果 |
Calcineurin inhibitors are immunosuppressants used to manage autoimmune conditions including but not limited to lupus nephritis, idiopathic inflammatory myositis, interstitial lung disease, atopic dermatitis, and many more. In addition, they are used as mainstays for immunosuppression in solid organ transplants.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Calcineurin Inhibitor estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Calcineurin Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Calcineurin Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Calcineurin Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Calcineurin Inhibitor include Accord Healthcare, Dr. Reddy Labs, Panacea Biotec Ltd., Sandoz, Mylan, Abbott, Roche Pharma, Astellas and Takeda, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Calcineurin Inhibitor companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Calcineurin Inhibitor market. Further, it explains the major drivers and regional dynamics of the global Calcineurin Inhibitor market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Accord Healthcare
Dr. Reddy Labs
Panacea Biotec Ltd.
Sandoz
Mylan
Abbott
Roche Pharma
Astellas
Takeda
Tecoland
ScinoPharm
RPG Life Science
Cayman Chemical
BioVision
Santa Cruz Biotechnology
Merck
AbMole
Selleck Chemicals
BOC Sciences
Biosynth Carbosynth
AG Scientific
TOKU-E
LKT Laboratories
Allergan
Mimetogen Pharmaceuticals
Otsuka Pharmaceutical
Regenerx Biopharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Calcineurin Inhibitor Segment by Type
Tacrolimus
Pimecrolimus
Cyclosporine A
Calcineurin Inhibitor Segment by Application
Chronic Graft-versus-host Disease
Atopic Dermatitis
Seborrheic Dermatitis
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Calcineurin Inhibitor market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Calcineurin Inhibitor market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Calcineurin Inhibitor, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Calcineurin Inhibitor, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Calcineurin Inhibitor revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Calcineurin Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Calcineurin Inhibitor revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Accord Healthcare, Dr. Reddy Labs, Panacea Biotec Ltd., Sandoz, Mylan, Abbott, Roche Pharma, Astellas and Takeda, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Calcineurin Inhibitor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Calcineurin Inhibitor companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Calcineurin Inhibitor revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Calcineurin Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Tacrolimus
1.2.3 Pimecrolimus
1.2.4 Cyclosporine A
1.3 Market by Application
1.3.1 Global Calcineurin Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Chronic Graft-versus-host Disease
1.3.3 Atopic Dermatitis
1.3.4 Seborrheic Dermatitis
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Calcineurin Inhibitor Market Perspective (2017-2028)
2.2 Calcineurin Inhibitor Growth Trends by Region
2.2.1 Calcineurin Inhibitor Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Calcineurin Inhibitor Historic Market Size by Region (2017-2022)
2.2.3 Calcineurin Inhibitor Forecasted Market Size by Region (2023-2028)
2.3 Calcineurin Inhibitor Market Dynamics
2.3.1 Calcineurin Inhibitor Industry Trends
2.3.2 Calcineurin Inhibitor Market Drivers
2.3.3 Calcineurin Inhibitor Market Challenges
2.3.4 Calcineurin Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Calcineurin Inhibitor Players by Revenue
3.1.1 Global Top Calcineurin Inhibitor Players by Revenue (2017-2022)
3.1.2 Global Calcineurin Inhibitor Revenue Market Share by Players (2017-2022)
3.2 Global Calcineurin Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Calcineurin Inhibitor Revenue
3.4 Global Calcineurin Inhibitor Market Concentration Ratio
3.4.1 Global Calcineurin Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Calcineurin Inhibitor Revenue in 2021
3.5 Calcineurin Inhibitor Key Players Head office and Area Served
3.6 Key Players Calcineurin Inhibitor Product Solution and Service
3.7 Date of Enter into Calcineurin Inhibitor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Calcineurin Inhibitor Breakdown Data by Type
4.1 Global Calcineurin Inhibitor Historic Market Size by Type (2017-2022)
4.2 Global Calcineurin Inhibitor Forecasted Market Size by Type (2023-2028)
5 Calcineurin Inhibitor Breakdown Data by Application
5.1 Global Calcineurin Inhibitor Historic Market Size by Application (2017-2022)
5.2 Global Calcineurin Inhibitor Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Calcineurin Inhibitor Market Size (2017-2028)
6.2 North America Calcineurin Inhibitor Market Size by Type
6.2.1 North America Calcineurin Inhibitor Market Size by Type (2017-2022)
6.2.2 North America Calcineurin Inhibitor Market Size by Type (2023-2028)
6.2.3 North America Calcineurin Inhibitor Market Share by Type (2017-2028)
6.3 North America Calcineurin Inhibitor Market Size by Application
6.3.1 North America Calcineurin Inhibitor Market Size by Application (2017-2022)
6.3.2 North America Calcineurin Inhibitor Market Size by Application (2023-2028)
6.3.3 North America Calcineurin Inhibitor Market Share by Application (2017-2028)
6.4 North America Calcineurin Inhibitor Market Size by Country
6.4.1 North America Calcineurin Inhibitor Market Size by Country (2017-2022)
6.4.2 North America Calcineurin Inhibitor Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Calcineurin Inhibitor Market Size (2017-2028)
7.2 Europe Calcineurin Inhibitor Market Size by Type
7.2.1 Europe Calcineurin Inhibitor Market Size by Type (2017-2022)
7.2.2 Europe Calcineurin Inhibitor Market Size by Type (2023-2028)
7.2.3 Europe Calcineurin Inhibitor Market Share by Type (2017-2028)
7.3 Europe Calcineurin Inhibitor Market Size by Application
7.3.1 Europe Calcineurin Inhibitor Market Size by Application (2017-2022)
7.3.2 Europe Calcineurin Inhibitor Market Size by Application (2023-2028)
7.3.3 Europe Calcineurin Inhibitor Market Share by Application (2017-2028)
7.4 Europe Calcineurin Inhibitor Market Size by Country
7.4.1 Europe Calcineurin Inhibitor Market Size by Country (2017-2022)
7.4.2 Europe Calcineurin Inhibitor Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Calcineurin Inhibitor Market Size (2017-2028)
8.2 Asia-Pacific Calcineurin Inhibitor Market Size by Type
8.2.1 Asia-Pacific Calcineurin Inhibitor Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Calcineurin Inhibitor Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Calcineurin Inhibitor Market Share by Type (2017-2028)
8.3 Asia-Pacific Calcineurin Inhibitor Market Size by Application
8.3.1 Asia-Pacific Calcineurin Inhibitor Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Calcineurin Inhibitor Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Calcineurin Inhibitor Market Share by Application (2017-2028)
8.4 Asia-Pacific Calcineurin Inhibitor Market Size by Region
8.4.1 Asia-Pacific Calcineurin Inhibitor Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Calcineurin Inhibitor Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Calcineurin Inhibitor Market Size (2017-2028)
9.2 Latin America Calcineurin Inhibitor Market Size by Type
9.2.1 Latin America Calcineurin Inhibitor Market Size by Type (2017-2022)
9.2.2 Latin America Calcineurin Inhibitor Market Size by Type (2023-2028)
9.2.3 Latin America Calcineurin Inhibitor Market Share by Type (2017-2028)
9.3 Latin America Calcineurin Inhibitor Market Size by Application
9.3.1 Latin America Calcineurin Inhibitor Market Size by Application (2017-2022)
9.3.2 Latin America Calcineurin Inhibitor Market Size by Application (2023-2028)
9.3.3 Latin America Calcineurin Inhibitor Market Share by Application (2017-2028)
9.4 Latin America Calcineurin Inhibitor Market Size by Country
9.4.1 Latin America Calcineurin Inhibitor Market Size by Country (2017-2022)
9.4.2 Latin America Calcineurin Inhibitor Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Calcineurin Inhibitor Market Size (2017-2028)
10.2 Middle East & Africa Calcineurin Inhibitor Market Size by Type
10.2.1 Middle East & Africa Calcineurin Inhibitor Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Calcineurin Inhibitor Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Calcineurin Inhibitor Market Share by Type (2017-2028)
10.3 Middle East & Africa Calcineurin Inhibitor Market Size by Application
10.3.1 Middle East & Africa Calcineurin Inhibitor Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Calcineurin Inhibitor Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Calcineurin Inhibitor Market Share by Application (2017-2028)
10.4 Middle East & Africa Calcineurin Inhibitor Market Size by Country
10.4.1 Middle East & Africa Calcineurin Inhibitor Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Calcineurin Inhibitor Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Accord Healthcare
11.1.1 Accord Healthcare Company Details
11.1.2 Accord Healthcare Business Overview
11.1.3 Accord Healthcare Calcineurin Inhibitor Introduction
11.1.4 Accord Healthcare Revenue in Calcineurin Inhibitor Business (2017-2022)
11.1.5 Accord Healthcare Recent Developments
11.2 Dr. Reddy Labs
11.2.1 Dr. Reddy Labs Company Details
11.2.2 Dr. Reddy Labs Business Overview
11.2.3 Dr. Reddy Labs Calcineurin Inhibitor Introduction
11.2.4 Dr. Reddy Labs Revenue in Calcineurin Inhibitor Business (2017-2022)
11.2.5 Dr. Reddy Labs Recent Developments
11.3 Panacea Biotec Ltd.
11.3.1 Panacea Biotec Ltd. Company Details
11.3.2 Panacea Biotec Ltd. Business Overview
11.3.3 Panacea Biotec Ltd. Calcineurin Inhibitor Introduction
11.3.4 Panacea Biotec Ltd. Revenue in Calcineurin Inhibitor Business (2017-2022)
11.3.5 Panacea Biotec Ltd. Recent Developments
11.4 Sandoz
11.4.1 Sandoz Company Details
11.4.2 Sandoz Business Overview
11.4.3 Sandoz Calcineurin Inhibitor Introduction
11.4.4 Sandoz Revenue in Calcineurin Inhibitor Business (2017-2022)
11.4.5 Sandoz Recent Developments
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Calcineurin Inhibitor Introduction
11.5.4 Mylan Revenue in Calcineurin Inhibitor Business (2017-2022)
11.5.5 Mylan Recent Developments
11.6 Abbott
11.6.1 Abbott Company Details
11.6.2 Abbott Business Overview
11.6.3 Abbott Calcineurin Inhibitor Introduction
11.6.4 Abbott Revenue in Calcineurin Inhibitor Business (2017-2022)
11.6.5 Abbott Recent Developments
11.7 Roche Pharma
11.7.1 Roche Pharma Company Details
11.7.2 Roche Pharma Business Overview
11.7.3 Roche Pharma Calcineurin Inhibitor Introduction
11.7.4 Roche Pharma Revenue in Calcineurin Inhibitor Business (2017-2022)
11.7.5 Roche Pharma Recent Developments
11.8 Astellas
11.8.1 Astellas Company Details
11.8.2 Astellas Business Overview
11.8.3 Astellas Calcineurin Inhibitor Introduction
11.8.4 Astellas Revenue in Calcineurin Inhibitor Business (2017-2022)
11.8.5 Astellas Recent Developments
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Calcineurin Inhibitor Introduction
11.9.4 Takeda Revenue in Calcineurin Inhibitor Business (2017-2022)
11.9.5 Takeda Recent Developments
11.10 Tecoland
11.10.1 Tecoland Company Details
11.10.2 Tecoland Business Overview
11.10.3 Tecoland Calcineurin Inhibitor Introduction
11.10.4 Tecoland Revenue in Calcineurin Inhibitor Business (2017-2022)
11.10.5 Tecoland Recent Developments
11.11 ScinoPharm
11.11.1 ScinoPharm Company Details
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Calcineurin Inhibitor Introduction
11.11.4 ScinoPharm Revenue in Calcineurin Inhibitor Business (2017-2022)
11.11.5 ScinoPharm Recent Developments
11.12 RPG Life Science
11.12.1 RPG Life Science Company Details
11.12.2 RPG Life Science Business Overview
11.12.3 RPG Life Science Calcineurin Inhibitor Introduction
11.12.4 RPG Life Science Revenue in Calcineurin Inhibitor Business (2017-2022)
11.12.5 RPG Life Science Recent Developments
11.13 Cayman Chemical
11.13.1 Cayman Chemical Company Details
11.13.2 Cayman Chemical Business Overview
11.13.3 Cayman Chemical Calcineurin Inhibitor Introduction
11.13.4 Cayman Chemical Revenue in Calcineurin Inhibitor Business (2017-2022)
11.13.5 Cayman Chemical Recent Developments
11.14 BioVision
11.14.1 BioVision Company Details
11.14.2 BioVision Business Overview
11.14.3 BioVision Calcineurin Inhibitor Introduction
11.14.4 BioVision Revenue in Calcineurin Inhibitor Business (2017-2022)
11.14.5 BioVision Recent Developments
11.15 Santa Cruz Biotechnology
11.15.1 Santa Cruz Biotechnology Company Details
11.15.2 Santa Cruz Biotechnology Business Overview
11.15.3 Santa Cruz Biotechnology Calcineurin Inhibitor Introduction
11.15.4 Santa Cruz Biotechnology Revenue in Calcineurin Inhibitor Business (2017-2022)
11.15.5 Santa Cruz Biotechnology Recent Developments
11.16 Merck
11.16.1 Merck Company Details
11.16.2 Merck Business Overview
11.16.3 Merck Calcineurin Inhibitor Introduction
11.16.4 Merck Revenue in Calcineurin Inhibitor Business (2017-2022)
11.16.5 Merck Recent Developments
11.17 AbMole
11.17.1 AbMole Company Details
11.17.2 AbMole Business Overview
11.17.3 AbMole Calcineurin Inhibitor Introduction
11.17.4 AbMole Revenue in Calcineurin Inhibitor Business (2017-2022)
11.17.5 AbMole Recent Developments
11.18 Selleck Chemicals
11.18.1 Selleck Chemicals Company Details
11.18.2 Selleck Chemicals Business Overview
11.18.3 Selleck Chemicals Calcineurin Inhibitor Introduction
11.18.4 Selleck Chemicals Revenue in Calcineurin Inhibitor Business (2017-2022)
11.18.5 Selleck Chemicals Recent Developments
11.19 BOC Sciences
11.19.1 BOC Sciences Company Details
11.19.2 BOC Sciences Business Overview
11.19.3 BOC Sciences Calcineurin Inhibitor Introduction
11.19.4 BOC Sciences Revenue in Calcineurin Inhibitor Business (2017-2022)
11.19.5 BOC Sciences Recent Developments
11.20 Biosynth Carbosynth
11.20.1 Biosynth Carbosynth Company Details
11.20.2 Biosynth Carbosynth Business Overview
11.20.3 Biosynth Carbosynth Calcineurin Inhibitor Introduction
11.20.4 Biosynth Carbosynth Revenue in Calcineurin Inhibitor Business (2017-2022)
11.20.5 Biosynth Carbosynth Recent Developments
11.21 AG Scientific
11.21.1 AG Scientific Company Details
11.21.2 AG Scientific Business Overview
11.21.3 AG Scientific Calcineurin Inhibitor Introduction
11.21.4 AG Scientific Revenue in Calcineurin Inhibitor Business (2017-2022)
11.21.5 AG Scientific Recent Developments
11.22 TOKU-E
11.22.1 TOKU-E Company Details
11.22.2 TOKU-E Business Overview
11.22.3 TOKU-E Calcineurin Inhibitor Introduction
11.22.4 TOKU-E Revenue in Calcineurin Inhibitor Business (2017-2022)
11.22.5 TOKU-E Recent Developments
11.23 LKT Laboratories
11.23.1 LKT Laboratories Company Details
11.23.2 LKT Laboratories Business Overview
11.23.3 LKT Laboratories Calcineurin Inhibitor Introduction
11.23.4 LKT Laboratories Revenue in Calcineurin Inhibitor Business (2017-2022)
11.23.5 LKT Laboratories Recent Developments
11.24 Allergan
11.24.1 Allergan Company Details
11.24.2 Allergan Business Overview
11.24.3 Allergan Calcineurin Inhibitor Introduction
11.24.4 Allergan Revenue in Calcineurin Inhibitor Business (2017-2022)
11.24.5 Allergan Recent Developments
11.25 Mimetogen Pharmaceuticals
11.25.1 Mimetogen Pharmaceuticals Company Details
11.25.2 Mimetogen Pharmaceuticals Business Overview
11.25.3 Mimetogen Pharmaceuticals Calcineurin Inhibitor Introduction
11.25.4 Mimetogen Pharmaceuticals Revenue in Calcineurin Inhibitor Business (2017-2022)
11.25.5 Mimetogen Pharmaceuticals Recent Developments
11.26 Otsuka Pharmaceutical
11.26.1 Otsuka Pharmaceutical Company Details
11.26.2 Otsuka Pharmaceutical Business Overview
11.26.3 Otsuka Pharmaceutical Calcineurin Inhibitor Introduction
11.26.4 Otsuka Pharmaceutical Revenue in Calcineurin Inhibitor Business (2017-2022)
11.26.5 Otsuka Pharmaceutical Recent Developments
11.27 Regenerx Biopharmaceuticals
11.27.1 Regenerx Biopharmaceuticals Company Details
11.27.2 Regenerx Biopharmaceuticals Business Overview
11.27.3 Regenerx Biopharmaceuticals Calcineurin Inhibitor Introduction
11.27.4 Regenerx Biopharmaceuticals Revenue in Calcineurin Inhibitor Business (2017-2022)
11.27.5 Regenerx Biopharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer